Prestige Biopharma IDC Files Patent for Anti-CTHRC1 Antibody Combination Therapy for Solid Tumors

[KOREAN]

[ENGLISH]

Prestige Biopharma IDC Files Patent for Anti-CTHRC1 Antibody Combination Therapy for Solid Tumors

Prestige Biopharma IDC (CEO: Sang-Seok Koh), the R&D center of Prestige Biopharma, announced that it has recently filed a domestic patent application for a pharmaceutical composition for anticancer combination therapy based on its anti-CTHRC1 monoclonal antibody candidate PBP1710.

Through this patent filing, the company aims to secure intellectual property rights related to PBP1710 while expanding strategic opportunities including global technology licensing, development of combination therapy kits, and potential entry into the companion diagnostics market.

The patent introduces a novel combination therapy strategy designed to overcome the limitations of conventional chemotherapy and improve treatment response rates in solid tumors. The approach focuses on regulating excessive accumulation of the extracellular matrix (ECM), which is known to hinder drug delivery within tumor tissues.

Prestige Biopharma IDC identified that the CTHRC1 protein, which is overexpressed in various solid tumors, promotes collagen accumulation within the ECM and creates a physical barrier that interferes with effective drug delivery. Based on this finding, the company designed a monoclonal antibody-based combination therapy targeting CTHRC1 to address this mechanism.

The core concept of the patent is the co-administration of the anti-CTHRC1 antibody PBP1710 with conventional anticancer drugs to enhance drug penetration and therapeutic responsiveness. By inhibiting CTHRC1 activity, PBP1710 improves the delivery efficiency of anticancer agents and amplifies the therapeutic effects of existing chemotherapy regimens.

Preclinical evaluations have demonstrated meaningful synergistic effects across several difficult-to-treat solid tumors, including triple-negative breast cancer (TNBC), ovarian cancer (OV), pancreatic ductal adenocarcinoma (PDAC), and glioblastoma (GBM). The antibody also showed compatibility with multiple chemotherapy agents such as paclitaxel, gemcitabine, and carboplatin.

Unlike conventional approaches that rely on ECM-degrading enzymes, this technology targets CTHRC1 to indirectly regulate collagen accumulation. This strategy may reduce systemic side effects and protect normal tissue while selectively suppressing pathological tumor mechanisms.

Because the antibody can potentially be combined with a wide range of anticancer drugs, the company views the technology as a versatile platform for anticancer combination therapies.

A company representative stated that the patent proposes a new therapeutic strategy that modulates ECM and collagen indirectly by targeting CTHRC1 rather than directly degrading structural components of the tumor microenvironment. The approach aims to minimize systemic toxicity while preserving normal tissue function and selectively inhibiting pathological processes.

The company plans to further develop the technology with the goal of expanding into global licensing opportunities, combination therapy kits, and companion diagnostic applications.

Source: Pax TV (https://www.paxetv.com/news/articleView.html?idxno=240157)